UA58565C2 - Инъекционный лекарственный препарат "цитофлавин", обладающий цитопротекторным действием - Google Patents
Инъекционный лекарственный препарат "цитофлавин", обладающий цитопротекторным действием Download PDFInfo
- Publication number
- UA58565C2 UA58565C2 UA2000052863A UA200052863A UA58565C2 UA 58565 C2 UA58565 C2 UA 58565C2 UA 2000052863 A UA2000052863 A UA 2000052863A UA 200052863 A UA200052863 A UA 200052863A UA 58565 C2 UA58565 C2 UA 58565C2
- Authority
- UA
- Ukraine
- Prior art keywords
- cytoflavin
- prototype
- animals
- effect
- cells
- Prior art date
Links
- 239000003814 drug Substances 0.000 title abstract description 20
- 229940079593 drug Drugs 0.000 title abstract description 19
- 230000001120 cytoprotective effect Effects 0.000 title abstract description 14
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 abstract description 21
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 abstract description 7
- 239000002207 metabolite Substances 0.000 abstract description 4
- 239000000203 mixture Substances 0.000 abstract description 4
- 239000001384 succinic acid Substances 0.000 abstract description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 abstract description 3
- 239000011734 sodium Substances 0.000 abstract description 3
- 229910052708 sodium Inorganic materials 0.000 abstract description 3
- JPXZQMKKFWMMGK-KQYNXXCUSA-K IDP(3-) Chemical compound O[C@@H]1[C@H](O)[C@@H](COP([O-])(=O)OP([O-])([O-])=O)O[C@H]1N1C(N=CNC2=O)=C2N=C1 JPXZQMKKFWMMGK-KQYNXXCUSA-K 0.000 abstract description 2
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 abstract description 2
- 229930010555 Inosine Natural products 0.000 abstract description 2
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 abstract description 2
- 229960003786 inosine Drugs 0.000 abstract description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 abstract 1
- 239000004615 ingredient Substances 0.000 abstract 1
- 239000002904 solvent Substances 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
- 239000008215 water for injection Substances 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 description 31
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 31
- 239000000243 solution Substances 0.000 description 24
- 210000004027 cell Anatomy 0.000 description 18
- 208000000418 Premature Cardiac Complexes Diseases 0.000 description 17
- 238000002474 experimental method Methods 0.000 description 17
- 241000700159 Rattus Species 0.000 description 14
- 210000003734 kidney Anatomy 0.000 description 14
- 206010003119 arrhythmia Diseases 0.000 description 12
- 230000006793 arrhythmia Effects 0.000 description 12
- 230000006870 function Effects 0.000 description 12
- 210000004185 liver Anatomy 0.000 description 12
- 241000699670 Mus sp. Species 0.000 description 10
- XFSBVAOIAHNAPC-XTHSEXKGSA-N 16-Ethyl-1alpha,6alpha,19beta-trimethoxy-4-(methoxymethyl)-aconitane-3alpha,8,10alpha,11,18alpha-pentol, 8-acetate 10-benzoate Chemical compound O([C@H]1[C@]2(O)C[C@H]3[C@@]45C6[C@@H]([C@@]([C@H]31)(OC(C)=O)[C@@H](O)[C@@H]2OC)[C@H](OC)[C@@H]4[C@]([C@@H](C[C@@H]5OC)O)(COC)CN6CC)C(=O)C1=CC=CC=C1 XFSBVAOIAHNAPC-XTHSEXKGSA-N 0.000 description 9
- XFSBVAOIAHNAPC-UHFFFAOYSA-N Aconitin Natural products CCN1CC(C(CC2OC)O)(COC)C3C(OC)C(C(C45)(OC(C)=O)C(O)C6OC)C1C32C4CC6(O)C5OC(=O)C1=CC=CC=C1 XFSBVAOIAHNAPC-UHFFFAOYSA-N 0.000 description 9
- 229940039750 aconitine Drugs 0.000 description 9
- STDXGNLCJACLFY-UHFFFAOYSA-N aconitine Natural products CCN1CC2(COC)C(O)CC(O)C34C5CC6(O)C(OC)C(O)C(OC(=O)C)(C5C6OC(=O)c7ccccc7)C(C(OC)C23)C14 STDXGNLCJACLFY-UHFFFAOYSA-N 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 210000002216 heart Anatomy 0.000 description 8
- 230000002107 myocardial effect Effects 0.000 description 8
- 230000001681 protective effect Effects 0.000 description 8
- 210000002700 urine Anatomy 0.000 description 8
- 210000003462 vein Anatomy 0.000 description 8
- 230000003288 anthiarrhythmic effect Effects 0.000 description 7
- 238000001990 intravenous administration Methods 0.000 description 7
- 235000018102 proteins Nutrition 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 6
- 210000004413 cardiac myocyte Anatomy 0.000 description 6
- 230000006378 damage Effects 0.000 description 6
- 230000003247 decreasing effect Effects 0.000 description 6
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 5
- 108010082126 Alanine transaminase Proteins 0.000 description 5
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 5
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 5
- DRBBFCLWYRJSJZ-UHFFFAOYSA-N N-methyl-N-phosphonocarbamimidoyl-glycine Natural products OC(=O)CN(C)C(=N)NP(O)(O)=O DRBBFCLWYRJSJZ-UHFFFAOYSA-N 0.000 description 5
- 230000004872 arterial blood pressure Effects 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 5
- 208000028867 ischemia Diseases 0.000 description 5
- 208000021241 Ethylene glycol poisoning Diseases 0.000 description 4
- 206010015856 Extrasystoles Diseases 0.000 description 4
- 229920002527 Glycogen Polymers 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 229940096919 glycogen Drugs 0.000 description 4
- 230000002443 hepatoprotective effect Effects 0.000 description 4
- 230000035987 intoxication Effects 0.000 description 4
- 231100000566 intoxication Toxicity 0.000 description 4
- 210000004165 myocardium Anatomy 0.000 description 4
- 201000008383 nephritis Diseases 0.000 description 4
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 230000003248 secreting effect Effects 0.000 description 4
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 3
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 3
- 108010024636 Glutathione Proteins 0.000 description 3
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 3
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 3
- 208000004880 Polyuria Diseases 0.000 description 3
- 208000001871 Tachycardia Diseases 0.000 description 3
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 230000007059 acute toxicity Effects 0.000 description 3
- 231100000403 acute toxicity Toxicity 0.000 description 3
- 230000002253 anti-ischaemic effect Effects 0.000 description 3
- 230000003851 biochemical process Effects 0.000 description 3
- 239000004202 carbamide Substances 0.000 description 3
- 150000003841 chloride salts Chemical class 0.000 description 3
- 230000035619 diuresis Effects 0.000 description 3
- 229960003180 glutathione Drugs 0.000 description 3
- 210000003494 hepatocyte Anatomy 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 230000007170 pathology Effects 0.000 description 3
- 239000000049 pigment Substances 0.000 description 3
- 230000006794 tachycardia Effects 0.000 description 3
- 206010057248 Cell death Diseases 0.000 description 2
- 208000008964 Chemical and Drug Induced Liver Injury Diseases 0.000 description 2
- 206010067125 Liver injury Diseases 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 108090000340 Transaminases Proteins 0.000 description 2
- 102000003929 Transaminases Human genes 0.000 description 2
- 230000001133 acceleration Effects 0.000 description 2
- 238000005903 acid hydrolysis reaction Methods 0.000 description 2
- 206010000891 acute myocardial infarction Diseases 0.000 description 2
- 229930013930 alkaloid Natural products 0.000 description 2
- 150000003797 alkaloid derivatives Chemical class 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 206010061592 cardiac fibrillation Diseases 0.000 description 2
- 230000003293 cardioprotective effect Effects 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 210000004351 coronary vessel Anatomy 0.000 description 2
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 2
- 229940109239 creatinine Drugs 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 210000001105 femoral artery Anatomy 0.000 description 2
- 210000003191 femoral vein Anatomy 0.000 description 2
- 230000002600 fibrillogenic effect Effects 0.000 description 2
- 230000005714 functional activity Effects 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 244000144993 groups of animals Species 0.000 description 2
- 231100000234 hepatic damage Toxicity 0.000 description 2
- 210000005229 liver cell Anatomy 0.000 description 2
- 230000008818 liver damage Effects 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 229940126601 medicinal product Drugs 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 208000031225 myocardial ischemia Diseases 0.000 description 2
- 238000010606 normalization Methods 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 229960003712 propranolol Drugs 0.000 description 2
- 230000001084 renoprotective effect Effects 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 229910001415 sodium ion Inorganic materials 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- MGSRCZKZVOBKFT-UHFFFAOYSA-N thymol Chemical compound CC(C)C1=CC=C(C)C=C1O MGSRCZKZVOBKFT-UHFFFAOYSA-N 0.000 description 2
- 238000009423 ventilation Methods 0.000 description 2
- MBDOYVRWFFCFHM-SNAWJCMRSA-N (2E)-hexenal Chemical compound CCC\C=C\C=O MBDOYVRWFFCFHM-SNAWJCMRSA-N 0.000 description 1
- 230000002407 ATP formation Effects 0.000 description 1
- 201000003126 Anuria Diseases 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- OKIBNKKYNPBDRS-UHFFFAOYSA-N Mefluidide Chemical compound CC(=O)NC1=CC(NS(=O)(=O)C(F)(F)F)=C(C)C=C1C OKIBNKKYNPBDRS-UHFFFAOYSA-N 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010030302 Oliguria Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000005374 Poisoning Diseases 0.000 description 1
- 206010038669 Respiratory arrest Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 239000005844 Thymol Substances 0.000 description 1
- 238000008050 Total Bilirubin Reagent Methods 0.000 description 1
- 208000009729 Ventricular Premature Complexes Diseases 0.000 description 1
- 206010047289 Ventricular extrasystoles Diseases 0.000 description 1
- 239000003929 acidic solution Substances 0.000 description 1
- 150000002952 aconitine derivatives Chemical class 0.000 description 1
- 238000005904 alkaline hydrolysis reaction Methods 0.000 description 1
- 239000012670 alkaline solution Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000036471 bradycardia Effects 0.000 description 1
- 208000006218 bradycardia Diseases 0.000 description 1
- QXDMQSPYEZFLGF-UHFFFAOYSA-L calcium oxalate Chemical compound [Ca+2].[O-]C(=O)C([O-])=O QXDMQSPYEZFLGF-UHFFFAOYSA-L 0.000 description 1
- JARKCYVAAOWBJS-UHFFFAOYSA-N caproic aldehyde Natural products CCCCCC=O JARKCYVAAOWBJS-UHFFFAOYSA-N 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 239000008139 complexing agent Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 229960003624 creatine Drugs 0.000 description 1
- 239000006046 creatine Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000005786 degenerative changes Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000005265 energy consumption Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- FVTCRASFADXXNN-SCRDCRAPSA-N flavin mononucleotide Chemical compound OP(=O)(O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O FVTCRASFADXXNN-SCRDCRAPSA-N 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 210000005248 left atrial appendage Anatomy 0.000 description 1
- 231100000225 lethality Toxicity 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000011206 morphological examination Methods 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 201000003144 pneumothorax Diseases 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229910001414 potassium ion Inorganic materials 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 210000005084 renal tissue Anatomy 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-N sodium;5-ethyl-5-pentan-2-yl-1,3-diazinane-2,4,6-trione Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)NC1=O QGMRQYFBGABWDR-UHFFFAOYSA-N 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229960000790 thymol Drugs 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- 210000005233 tubule cell Anatomy 0.000 description 1
- 238000005353 urine analysis Methods 0.000 description 1
- 208000003663 ventricular fibrillation Diseases 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Saccharide Compounds (AREA)
Abstract
Изобретение относится к медицине, в частности к инъекционному лекарственному препарату, обладающему цитопротекторным действием. В состав препарата входит активная композиция природных метаболитов и коферментов в растворителе. В качестве природных метаболитов используют янтарную кислоту и рибоксин (инозин), в качестве коферментов – никотинамид и рибофлавин-5-мононуклеотид в виде натриевой соли. Растворителем служит вода для инъекций. Кроме того, в состав препарата входит гидроокись натрия и N-метилглюкамин.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EA199900510A EA001099B1 (ru) | 1999-06-10 | 1999-06-10 | Инъекционное лекарственое средство "цитофлавин", обладающее цитопротекторным действием |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA58565C2 true UA58565C2 (ru) | 2003-08-15 |
Family
ID=8161492
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UA2000052863A UA58565C2 (ru) | 1999-06-10 | 2000-05-19 | Инъекционный лекарственный препарат "цитофлавин", обладающий цитопротекторным действием |
Country Status (2)
| Country | Link |
|---|---|
| EA (1) | EA001099B1 (ru) |
| UA (1) | UA58565C2 (ru) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2463045C1 (ru) * | 2011-05-12 | 2012-10-10 | Общество с ограниченной ответственностью "МЕЖДУНАРОДНЫЙ ЦЕНТР КЛИНИЧЕСКОЙ ЛИМФОЛОГИИ" | Способ лечения цереброваскулярных заболеваний и астенического синдрома |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2302227C2 (ru) * | 2005-08-01 | 2007-07-10 | Борис Васильевич Метелкин | Способ лечения наркомании |
| RU2456011C1 (ru) * | 2010-12-22 | 2012-07-20 | Закрытое Акционерное Общество Научно-Производственный Центр "Борщаговский Химико-Фармацевтический Завод" | Средство "фларосукцин" для лечения и профилактики заболеваний почек и мочевыводящей системы |
| RU2462280C1 (ru) * | 2011-07-14 | 2012-09-27 | Федеральное государственное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова Федерального агентства по высокотехнологичной медицинской помощи" | Способ цитофлавин-электрокумуляции при лечении сосудистых и дистрофических заболеваний сетчатки и зрительного нерва |
| RU2547565C1 (ru) * | 2013-11-12 | 2015-04-10 | Государственное бюджетное образовательное учреждение высшего профессионального образования "Ростовский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ГБОУ ВПО РостГМУ Минздрава России) | Способ лечения пациентов с абузусной головной болью |
| UA111116C2 (uk) * | 2014-05-20 | 2016-03-25 | Екофарм Патєнт Менеджмент Аг | Збалансований інфузійний розчин |
| RU2629204C1 (ru) * | 2016-09-29 | 2017-08-25 | Общество С Ограниченной Ответственностью "Научно-Технологическая Фармацевтическая Фирма "Полисан" | Способ получения стабилизированной фармацевтической композиции в виде водного раствора |
| RU2629019C1 (ru) * | 2016-10-10 | 2017-08-24 | федеральное государственное бюджетное учреждение "Северо-Западный федеральный медицинский исследовательский центр имени В.А. Алмазова" Министерства здравоохранения Российской Федерации | Способ интраоперационного предупреждения локального ишемического повреждения головного мозга при микрохирургической операции по поводу церебральной артериальной аневризмы |
| RU2651047C1 (ru) * | 2017-05-04 | 2018-04-18 | Общество С Ограниченной Ответственностью "Научно-Технологическая Фармацевтическая Фирма "Полисан" | Лекарственная композиция цитопротекторного действия и способ ее получения |
| EA030458B1 (ru) * | 2017-05-23 | 2018-08-31 | Общество С Ограниченной Ответственностью "Научно-Технологическая Фармацевтическая Фирма "Полисан" | Лекарственная композиция цитопротекторного действия в виде водного раствора для внутривенного введения и способ ее получения |
-
1999
- 1999-06-10 EA EA199900510A patent/EA001099B1/ru not_active IP Right Cessation
-
2000
- 2000-05-19 UA UA2000052863A patent/UA58565C2/ru unknown
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2463045C1 (ru) * | 2011-05-12 | 2012-10-10 | Общество с ограниченной ответственностью "МЕЖДУНАРОДНЫЙ ЦЕНТР КЛИНИЧЕСКОЙ ЛИМФОЛОГИИ" | Способ лечения цереброваскулярных заболеваний и астенического синдрома |
Also Published As
| Publication number | Publication date |
|---|---|
| EA001099B1 (ru) | 2000-10-30 |
| EA199900510A1 (ru) | 2000-08-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Knochel | Rhabdomyolysis and myglobinuria | |
| EA010948B1 (ru) | Фармацевтическая композиция, содержащая лактат, и ее применение | |
| UA58565C2 (ru) | Инъекционный лекарственный препарат "цитофлавин", обладающий цитопротекторным действием | |
| US4927817A (en) | Preventive and therapeutic agent against liver disorder | |
| KEITH et al. | The action and excretion of nitrates | |
| CN114191425A (zh) | 2,4-二羟基苯甲酸在治疗铁过载疾病食品药品中的应用 | |
| BOUNOUS et al. | Dietary prevention of experimental shock lesions | |
| WO2017112574A1 (en) | Pharmaceutical formulations for treating kidney stones and methods for fabricating and using thereof | |
| Althausen | Dextrose therapy in diseases of the liver | |
| RU2096034C1 (ru) | Фармацевтическая композиция, индуцирующая биосинтез глутатиона, активность глутатионтрансферазы и оказывающая антитоксическое, радиопротекторное и антигипоксическое действие, и способы лечения, профилактики и защиты с ее использованием | |
| US5240700A (en) | Pharmaceutical composition comprising a medicament and 3-oxygermylpropionic acid | |
| RU2283114C1 (ru) | Композиция, обладающая гепатопротекторной активностью и нормализующая обменные процессы | |
| AU651824B2 (en) | Pharmaceutical composition | |
| RU2178296C1 (ru) | Инфузионный раствор для лечения заболеваний сердечно-сосудистой системы | |
| EP0755681A1 (en) | Tungsten (VI) compositions for the oral treatment of diabetes mellitus | |
| WO2002038152A1 (es) | Combinacion de aminas y compuestos de vanadio (iv)/(v) para el tratamiento y/o la prevencion de la diabetes mellitus | |
| Alexander et al. | Inhibition of Aminonucleoside Nephrosis in Rats: I. The Effect of Adenine, Adenosine and Adenosine Triphosphate | |
| Moore | Lead and the mitochondrion | |
| Friend | Iron ascorbate in the treatment of anemia | |
| Bruch | Recent progress in insulin physiology | |
| JPH0971528A (ja) | 抗腫瘍剤 | |
| Vorob’ev et al. | Colloid-chemical and medico-biological characteristics of the perfluorocarbon Ftoremulsion III | |
| Wyss et al. | δ-Aminolevulinic acid dehydratase: Effects of succinylacetone in rat liver and kidney in an in vivo model of the renal Fanconi syndrome | |
| Cow et al. | The action of dimethyltellurium dihaloids | |
| WO2025102364A1 (zh) | 具有护肾功效的咪唑二肽组合物及其应用 |